Barclays initiated coverage of 4D Molecular with an Overweight rating and $459 price target. The analyst believes 4D-150 has provided an important validation of 4D Molecular’s AAV platform. The company’s current clinical profile could support meaningful market potential in age-related macular degeneration if proven to be durable, with additional upside from other indications and pipeline assets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular assumed with a Buy at Jefferies
- 4D Molecular price target lowered to $63 from $70 at BMO Capital
- 4D Molecular announce update on regulatory interactions, development for 4D-710
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
